Erelzi: Additional Ph III EGALITY data

Additional data from the switching portion of the double-blind, international Phase III EGALITY trial showed no clinically meaningful differences in safety and efficacy in patients who alternated between treatment with Erelzi and Enbrel etanercept. The trial enrolled 531

Read the full 381 word article

User Sign In